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Abstract
Background: It is widely assumed that voluntary counselling and testing (VCT) services contribute to HIV prevention by
motivating clients to reduce sexual risk-taking. However, findings from sub-Saharan Africa have been mixed, particularly
among HIV-negative persons. We explored associations between VCT use and changes in sexual risk behaviours and HIV
incidence using data from a community HIV cohort study in northwest Tanzania.
Methods: Data on VCT use, sexual behaviour and HIV status were available from three HIV serological surveillance rounds
undertaken in 2003–4 (Sero4), 2006–7 (Sero5) and 2010 (Sero6). We used multinomial logistic regression to assess
changes in sexual risk behaviours between rounds, and Poisson regression to estimate HIV incidence.
Results: The analyses included 3,613 participants attending Sero4 and Sero5 (3,474 HIV-negative and 139 HIV-positive at
earlier round) and 2,998 attending Sero5 and Sero6 (2,858 HIV-negative and 140 HIV-positive at earlier round). Among
HIV-negative individuals VCT use was associated with reductions in the number of sexual partners in the last year (aRR
Seros 4–5: 1.42, 95% CI 1.07-1.88; aRR Seros 5–6: 1.68, 95% CI 1.25-2.26) and in the likelihood of having a non-cohabiting
partner in the last year (aRR Seros 4–5: 1.57, 95% CI 1.10-2.25; aRR Seros 5–6: 1.48, 95% CI 1.07-2.04) or a high-risk partner
in the last year (aRR Seros 5–6 1.57, 95% CI 1.06-2.31). However, VCT was also associated with stopping using condoms
with non-cohabiting partners between Seros 4–5 (aRR 4.88, 95% CI 1.39-17.16). There were no statistically significant
associations between VCT use and changes in HIV incidence, nor changes in sexual behaviour among HIV-positive
individuals, possibly due to small sample sizes.
Conclusions: We found moderate associations between VCT use and reductions in some sexual risk behaviours
among HIV-negative participants, but no impacts among HIV-positive individuals in the context of low overall VCT
uptake. Furthermore, there were no significant changes in HIV incidence associated with VCT use, although declining
background incidence and small sample sizes may have prevented us from detecting this. The impact of VCT services will
ultimately depend upon rates of uptake, with further research required to better understand processes of behaviour
change following VCT use.
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Background
Voluntary counselling and testing (VCT) for HIV has
been promoted as a gateway for access to HIV treatment
and care. Concurrently, the services’ potential contribution
to HIV prevention has been emphasized; it is hypothesized
that knowledge of HIV sero-status, accompanied by tailored
and targeted risk reduction counselling, will assist both
HIV-negative and HIV-positive individuals to reduce sexual
risk-taking and protect themselves and their partners from
HIV [1,2]. Previous studies have found mixed results with
regard to the impact of VCT on reductions in sexual risk
behaviour. These have generally found greater impact
among individuals testing HIV-positive compared to those
testing negative [3-5]. However, some studies have found
no association between VCT use and changes in sexual be-
haviour [6,7], while others have found increases in sexual
risk taking among individuals testing HIV-negative [8]. Few
studies have assessed the impact of VCT on HIV incidence,
however overall, these have found no significant differences
between participants who received and did not receive
VCT [5].
The measurement and comparison of indicators of
sexual risk behaviour over time and between populations
is difficult for a number of reasons, possibly explaining
previous ambiguous findings regarding the impact of
VCT on sexual behaviour change. Firstly, self-reported
sexual behaviour data are often subject to recall and
social desirability biases, the levels of which may vary
depending on the behaviour in question, the amount of
time that has passed since the event, and past exposure
to HIV prevention messages [9]. Secondly, developing
measures or indicators of sexual risk behaviour which
are specific enough to accurately capture information on
an individual’s sexual risk profile, yet general enough to
be comparable across populations or over time, is diffi-
cult [10]. Nevertheless, while measures of sexual behav-
iour have not always correlated well with rates of HIV
incidence or prevalence [11-13], trends in these indica-
tors have aided our understanding of the HIV epidemic
and its relationship with sexual risk behaviour [14].
In this paper, we assess the impact of VCT use on
changes in reported sexual risk behaviours and HIV in-
cidence using data from consecutive rounds of HIV
serological surveillance (sero-surveys) which have been
carried out as part of an on-going community cohort
study in northwest Tanzania since 1994. VCT services
were provided during three sero-surveys in 2003–4,
2006–7 and 2010.
Methods
Study setting
The study setting in Mwanza region has been described
in detail by Mwaluko et al. [15]. Briefly, the study area
lies approximately 20 km to the east of Mwanza city and
consists of six villages which make up the administrative
ward of Kisesa with a combined population of approxi-
mately 32,000 people, roughly half of whom are adults.
The cohort consists of rounds of demographic surveil-
lance taking place approximately once every six months
since 1994, and rounds of HIV serological surveillance
among adults aged 15 or older once every two to three
years. HIV prevalence in the study area rose from 6.0%
(95% CI 5.3% to 6.4%) in 1994–5 to 8.2% (95% CI 7.7%
to 8.8%) in 2003–4 [16], before falling to 6.5% (95% CI
6.0% to 7.0%) in 2010 (R. Isingo, personal communica-
tion). This pattern may be explained by net in-migration
of HIV infected individuals into the study area in the
1990’s, and a falling HIV incidence in the study area
since the late 1990s [17].
Sero-surveys take place at a central point in each village,
with dry-blood spot samples taken for ascertainment of
HIV-status using a protocol based on informed consent
without disclosure. HIV diagnosis is based on two ELIZAs
(Uniform 2, Enzygnost HIV1/HIV2). A detailed question-
naire is administered by same sex interviewers, covering
topics on socio-demographic characteristics, sexual behav-
iour and participants’ previous use of VCT services includ-
ing the place and circumstances of testing, e.g. whether at a
previous sero-survey or elsewhere (and if so, where).
Since the fourth sero-survey round in 2003–4 (Sero4),
a separate VCT service following Tanzanian national
guidelines and including pre- and post-test counselling
[18] has been available to all study participants. Individuals
wishing to know their HIV status are directed to a purpose-
constructed hut for VCT with a trained counsellor directly
after completing their questionnaire interview. At Sero4,
venous blood was collected and transported to the National
Institute for Medical Research (NIMR) in Mwanza, with
diagnosis based on two ELIZAs as for research tests, and
clients asked to return for their test results and post-test
counselling one week later. During the fifth and sixth sero-
survey rounds in 2006–7 (Sero5) and 2010 (Sero6) venous
blood was again collected but rapid HIV screening tests
were used (preliminary test using Capillus, confirmatory
test using Determine. Discrepant results resolved using two
ELIZAs as for research tests). Quality control was per-
formed at the NIMR laboratory on a 5% sub-sample using
two ELIZAs. During Sero5 and Sero6, HIV results and
post-test counselling were usually available within 45 mi-
nutes of the rapid test being performed. Data on the uptake
of VCT at sero-surveys are anonymously linked to the main
sero-survey questionnaire using unique numerical partici-
pant identifiers.
Although free antiretroviral therapy (ART) was not
available in 2003–4, individuals with an HIV-positive
result after using VCT at Sero4 were informed that treat-
ment would become available in the region in the near fu-
ture through the national ART programme, which started
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at the beginning of 2005. With their prior agreement, these
individuals were subsequently traced by the VCT counsel-
lors and referred to the zonal referral hospital in Mwanza
city for follow-up care. Individuals using VCT and testing
HIV-positive at Sero5 were referred directly to Mwanza city
hospitals. By Sero6 in 2010, a care and treatment centre
was available locally at the health centre in Kisesa and so
HIV-positive patients were referred here.
Other health services in the study area
The study population is served by a government-run
health centre located in Kisesa trading centre, by three
small government-run dispensaries located in the rural
villages, and by a number of private clinics located
mainly in the trading centre. A stand-alone VCT clinic
has been available at Kisesa health centre since 2005,
while provider initiated testing and counselling (PITC)
has been offered to all pregnant women attending the
health centre for antenatal care since the end of 2008.
PITC has also been available at the out-patients depart-
ment since 2010, where testing may be offered to patients
attending the sexually transmitted infections or tuberculosis
clinics. Since mid-2009, antenatal PITC is sometimes
offered to women attending the small rural dispensar-
ies, dependant on the availability of test-kit supplies.
Ethical statement
Ethical approval for the Kisesa cohort study has been
granted by the Tanzanian Medical Research Coordinat-
ing Committee and the Ethics Committee of the London
School of Hygiene and Tropical Medicine. Participation
is based on informed consent without disclosure of HIV-
research test results, however since Sero4 (just prior to
the introduction of ART), participants are additionally
offered a free VCT service as detailed above. During
Sero4 verbal consent was obtained, due to low literacy
rates among the study population. This was witnessed
and documented for each participant on their study
questionnaire, by a member of the sero-survey team.
During Sero5 and Sero6 written consent was introduced
(either a signature or a thumb-print, depending on the
participant’s writing ability).
Data and analysis
Nine indices of sexual behaviour were used: the number
of sex partners in the last year, the acquisition or loss of
spouse, regular non-cohabiting sexual partner, or high
risk sex partner in the last year, whether a condom was
used with spouse, regular non-cohabiting sexual partner,
or high risk partner at last sex, and the coital frequency
with spouse or regular non-cohabiting sexual partner in
the last week. Changes in sexual behaviour were deter-
mined by comparing behaviours reported at one round
with those reported at the next, in order to determine
whether there had been an increase, decrease or no change
in behaviour. For quantitative variables (number of sexual
partners, coital frequency), differences in the constructed
behaviour change variables greater than zero indicated an
increase in sexual risk behaviour while values less than zero
indicated a decrease and a value of zero indicated no
change. For changes in binary variables (condom use at last
sex), the indices represented the direction of change in be-
haviour, with 1 representing increased risk, 0 no change
and −1 decreased risk. Multinomial logistic regression was
used to assess the association between VCT and each of the
nine indices of sexual behaviour change. Crude associations
were adjusted for socio-demographic variables (age, sex,
marital status, area of residence, level of education and re-
ported previous use of VCT) in multivariable analyses.
In order to explore any potential differences over time,
analyses were carried out separately for those a) attending
both Sero4 and Sero5 and using the VCT service at Sero4,
b) attending both Sero5 and Sero6 and using the VCT ser-
vice at Sero5. Analyses were restricted to the non-virgin
population (those who reported having ever had sex) and
considered separately for individuals testing HIV-negative
and HIV-positive at the time of going for VCT.
HIV incidence was estimated based on the number of
initially HIV-negative respondents who seroconverted
between Seros 4 and 5, and Seros 5 and 6, respectively.
Dates of sero-conversion were assigned based on the mid-
point between sero-survey interview dates. Poisson regres-
sion models were used to calculate crude and adjusted HIV
incidence rates comparing VCT users and non-users.
Results
Descriptive characteristics
In total 8,961 participants attended Sero4 (participa-
tion rate of 66% [16]), of whom 3,923 (43.8%) also
attended Sero5. Of these, 3,613/3,923 (92.1%) reported
that they had ever had sex. 933/3,613 (25.8%) individuals
expressed a desire for VCT while 324/3,613 (9.0%) actually
returned to receive their results and complete VCT. In total
8,696 participants attended Sero5 (participation rate of 61%
[17]), of whom 3,509 also attended Sero6 (40.3%), with
2,998/3,509 (85.4%) reporting having ever had sex. Of these,
525/2,998 (17.5%) individuals expressed a desire for VCT
while 532/2,998 (17.7%) actually completed VCT. The de-
scriptive characteristics of the non-virgin population at-
tending the two sets of sero-survey rounds are shown in
Table 1. The largest proportions of attendees were female
and fell in the ≥45 age-group. Of those attending Sero4 and
Sero5, 139/3,613 participants (3.8%) were HIV-positive,
while 23/324 (7.1%) of those who used VCT at Sero4 were
HIV-positive. Of those attending Sero5 and Sero6, 140/
2,998 (4.7%) were HIV-positive and 29/532 (5.4%) of those
who used VCTat Sero5 were HIV-positive.
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Across both sets of rounds, approximately 60% of at-
tendees were married monogamously with a further 10%
being in polygamous marriages. Most participants reported
having one sexual partner (in the last year), and not having
any regular non-cohabiting or high risk partners (also in
the last year - Table 1). Condom use was rare, with just
7.4% reporting ever using a condom at Sero4, and 9.2%
reporting ever using a condom with the three most recent
sexual partners at Sero5.
Impact of VCT on sexual behaviour change among
HIV-negative individuals
Among HIV-negative individuals, VCT use was associ-
ated with some changes in sexual behaviour in terms of
the number and type of partnerships formed, but less so
in terms of condom use or coital frequency (see Tables 2
and 3). Between Sero4 and Sero5, compared to those
who did not have VCT, VCT users had an increased like-
lihood of reducing their number of sexual partners in
the last year (Table 2: adjusted risk ratio [aRR] 1.42, 95%
confidence interval [CI] 1.07-1.88). A similar pattern
was seen in terms of reduction in the number of sexual
partners between Sero5 and Sero6 (Table 3: aRR 1.68,
95% CI 1.25-2.26).
Among HIV negative individuals, there was evidence
that VCT use at Sero4 was associated with both acquir-
ing (aRR 1.88, 95% CI 1.29-2.74) and losing (aRR 1.56,
95% CI 0.95-2.55) a spouse by Sero5 (Table 2). While
Table 1 Characteristics (at earlier round) of individuals attending i)Sero-4 and Sero-5, ii)Sero-5 and Sero-6, by VCT use
at earlier round
Attended Sero4 and Sero5 Attended Sero5 and Sero6
No VCT Had VCT Total No VCT Had VCT Total
N (%) N (%)N (%) N (%)
Total 3289 (91.0) 324 (9.0) 3613 (100) 2466 (82.3) 532 (17.7) 2998 (100)
Sex Male 1228 (87.1) 182 (12.9) 1420 (100) 795 (78.5) 218 (21.5) 1013 (100)
Female 2061 (93.6) 142 (6.4) 2203 (100) 1671 (84.2) 314 (15.8) 1985 (100)
Age 15-24 815 (92.1) 70 (7.9) 885 (100) 480 (80.8) 114 (19.2) 594 (100)
25-34 731 (86.7) 112 (13.3) 843 (100) 549 (78.1) 154 (21.9) 703 (100)
35-44 673 (89.4) 80 (10.6) 753 (100) 471 (77.2) 139 (22.8) 610 (100)
> = 45 1070 (94.5) 62 (5.5) 1132 (100) 966 (88.5) 125 (11.5) 1091 (100)
HIV status Negative 3173 (91.3) 301 (8.7) 3474 (100) 2355 (82.4) 503 (17.6) 2858 (100)
Positive 116 (83.5) 23 (16.5) 139 (100) 111 (79.3) 29 (20.7) 140 (100)
Reported previous use of VCT$* No 3046 (92.2) 258 (7.8) 3304 (100) 1667 (88.9) 208 (11.1) 1875 (100)
Yes 243 (78.6) 66 (21.4) 309 (100) 728 (69.7) 317 (30.3) 1045 (100)
Number of sexual partners in last year None 392 (97.5) 10 (2.5) 402 (100) 490 (92.3) 41 (7.7) 531 (100)
One 2195 (91.8) 195 (8.2) 2390 (100) 1755 (81.8) 390 (18.2) 2145 (100)
Two or more 702 (85.5) 119 (14.5) 821 (100) 221 (68.6) 101 (31.4) 322 (100)
Marital status$β Never married 435 (88.8) 55 (11.2) 490 (100) 294 (81.4) 67 (18.6) 361 (100)
Marr monogamous 1946 (90.9) 195 (9.1) 2141 (100) 1392 (80.7) 332 (19.3) 1724 (100)
Marr polygamous 303 (91.0) 30 (9.0) 333 (100) 268 (81.2) 62 (18.8) 330 (100)
Widowed 276 (92.9) 21 (7.1) 297 (100)
Separated/divorced 236 (82.5) 50 (17.5) 286 (100)
Widowed/Separated 568 (93.4) 40 (6.6) 608 (100)
Regular non-cohabiting partner in last year$ No 2776 (92.0) 242 (8.0) 3018 (100) 2130 (83.7) 415 (16.3) 2545 (100)
Yes 513 (86.2) 82 (13.8) 595 (100) 331 (74.2) 115 (25.8) 446 (100)
High risk partner in last year$ No 3185 (91.3) 302 (8.7) 3487 (100) 2297 (83.0) 471 (17.0) 2768 (100)
Yes 104 (82.5) 22 (17.5) 126 (100) 157 (73.7) 56 (26.3) 213 (100)
Ever used a condom$# No 2907 (92.6) 231 (7.4) 3138 (100) 1778 (81.9) 393 (18.1) 2171 (100)
Yes 380 (80.3) 93 (19.7) 473 (100) 133 (64.3) 74 (35.7) 207 (100)
$Small numbers of missing data (<3%).
*This was previous VCT use as reported at the later round (to account for any VCT use in the inter sero-survey period).
βData on widowed/separated not broken down at Sero4.
#At Sero5 this variable related to ever use of condoms with spouse or regular non-cohabiting partners only (N = 2,403).
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similar trends were seen between Sero5 and Sero6, the
results were not statistically significant (Table 3 aRR for
acquiring a spouse: 1.19, 95% CI 0.82-1.73; aRR for los-
ing a spouse: 1.12, 95% CI 0.74-1.70). Between Seros 4
and 5 and also between Seros 5 and 6, VCT use at the
earlier round was also significantly associated with losing
a regular non-cohabiting partner by the later round
(aRR Seros 4–5: 1.57, 95% CI 1.10-2.25, aRR Seros 5–6:
1.48, 95% CI 1.07-2.04). Further investigation revealed
that approximately half of those who acquired a spouse
Table 2 Change in sexual behaviour between Sero4 and Sero5 associated with VCT use at Sero4, HIV-negative
individuals
N with outcome (%)
No VCT Had VCT Crude risk ratio (95% CI) Adjusted risk ratio (95% CI)¶
Number of sex partners in last year
3173 % 301 %
No change 2060 64.9 169 56.1 1
Increase 306 9.6 25 8.3 1 (0.64-1.54) 0.82 (0.52-1.30)
Decrease 807 25.4 107 35.5 1.62 (1.25-2.09)*** 1.42 (1.07-1.88)**
Acquired or lost a spouseα
3136 % 297 %
No change 2701 86.1 233 78.5 1 1
Acquired 255 8.1 43 14.5 1.95 (1.38-2.77)*** 1.88 (1.29-2.74)***
Lost 180 5.7 21 7.1 1.35 (0.84-2.17) 1.56 (0.95-2.55)*
Acquired or lost a regular non-cohabiting partner
3168 % 301 %
No change 2601 82.1 226 75.1 1 1
Acquired 251 7.9 27 9.0 1.24 (0.81-1.88) 0.88 (0.55-1.43)
Lost 316 10.0 48 15.9 1.75 (1.25-2.44)*** 1.57 (1.10-2.25)**
Acquired or lost a high risk partner
3156 % 299 %
No change 2879 91.2 267 89.3 1 1
Acquired 193 6.1 19 6.4 1.06 (0.65-1.73) 0.97 (0.58-1.62)
Lost 84 2.7 13 4.3 1.67 (0.92-3.03) 1.41 (0.75-2.65)
Condom use at last sex with spouse#
2000 % 190 %
No change 1951 97.6 184 96.8 1 1
Stopped using 31 1.6 2 1.1 0.68 (0.16-2.88) 0.45 (0.10-1.93)
Started using 18 0.9 4 2.1 2.36 (0.79-7.04) 1.79 (0.56-5.67)
Condom use at last sex with regular non-cohabiting partner#
179 % 31 %
No change 147 82.1 17 54.8 1 1
Stopped using 12 6.7 8 25.8 5.76 (2.07-16.08)*** 4.88 (1.39-17.16)**
Started using 20 11.2 6 19.4 2.59 (0.92-7.35) 2.21 (0.60-8.14)
Condom use at last sex with high risk partner#
12 % 5 %
No change 8 66.7 3 60.0 1 -
Stopped using 1 8.3 1 20.0 2.67 (0.12-57.62) -
Started using 3 25.0 1 20.0 0.89 (0.06-12.25) -
¶All outcomes adjusted for age, sex, marital status, area of residence, level of education and previous VCT use as reported at the later sero-survey round.
*p ≤ 0.1, **p ≤ 0.05, ***p ≤ 0.001.
α‘Acquired or lost spouse’ was not adjusted for marital status (as this was the outcome).
#Analyses conduced among those with relevant partner type at both rounds only.
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Table 3 Change in sexual behaviour between Sero5 and Sero6 associated with VCT use at Sero5, HIV-negative
individuals
N with outcome (%)
No VCT Had VCT Crude risk ratio (95% CI) Adjusted risk ratio (95% CI)¶
Number of sex partners in last year
2336 % 502 %
No change 1732 74.1 338 67.3 1 1
Increase 272 11.6 74 14.7 1.39 (1.05, 1.85)** 1.13 (0.82, 1.55)
Decrease 332 14.2 90 17.9 1.39 (1.07, 1.80)** 1.68 (1.25, 2.26)***
Acquired or lost a spouseα
2346 % 500 %
No change 2043 87.1 423 84.6 1 1
Acquired 158 6.7 44 8.8 1.35 (0.95, 1.91)* 1.19 (0.82, 1.73)
Lost 145 6.2 33 6.6 1.1 (0.74, 1.63) 1.12 (0.74, 1.70)
Acquired or lost a regular non-cohabiting partner
2350 % 501 %
No change 2017 85.8 399 79.6 1 1
Acquired 90 3.8 23 4.6 1.29 (0.81, 2.07) 1.23 (0.73, 2.07)
Lost 243 10.3 79 15.8 1.64 (1.25, 2.16)*** 1.48 (1.07, 2.04)**
Acquired or lost a high risk or casual partnerΩ
2344 % 498 %
No change 2062 88.0 406 81.5 1 1
Acquired 153 6.5 48 9.6 1.59 (1.13, 2.24)** 1.28 (0.84, 1.95)
Lost 129 5.5 44 8.8 1.73 (1.21, 2.48)** 1.57 (1.06, 2.31)**
Condom use at last sex with spouse#
1379 % 332 %
No change 1345 97.5 326 98.2 1 1
Stopped using 18 1.3 3 0.9 0.69 (0.20, 2.35) 0.64 (0.18, 2.28)
Started using 16 1.2 3 0.9 0.77 (0.22, 2.67) 0.62 (0.17, 2.29)
Condom use at last sex with regular non-cohabiting partner#
75 % 29 %
No change 51 68.0 20 69.0 1 1
Stopped using 12 16.0 5 17.2 1.06 (0.33, 3.40) 0.70 (0.14, 3.54)
Started using 12 16.0 4 13.8 0.85 (0.24, 2.95) 0.32 (0.06, 1.63)
Condom use at last sex with high risk or casual partner#Ω
18 % 10 %
No change 10 55.6 6 60.0 1 1
Stopped using 1 5.6 2 20.0 3.33 (0.25, 45.11) -
Started using 7 38.9 2 20.0 0.48 (0.07, 3.09) -
Number times sex with spouse in last week#
1388 % 335 %
No change 384 27.7 81 24.2 1 1
Increase 296 21.3 68 20.3 1.09 (0.76, 1.56) 1.03 (0.71, 1.51)
Decrease 708 51.0 186 55.5 1.25 (0.93, 1.66) 1.3 (0.96, 1.77)
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by the later round were the same people who had lost a
regular non-cohabiting partner (144/298 or 48.3% of
those acquiring a spouse between Sero4 and Sero5, and
106/202 or 52.5% of those acquiring a spouse between
Sero5 and Sero6). As a result, at least some of the spou-
sal acquisition between rounds is likely as a result of
people marrying their regular partners. Between Seros 5
and 6, VCT use was also associated with losing a high-
risk or casual partner (aRR 1.57, 95% CI 1.06-2.31).
In general there was no significant impact of VCT on
condom use behaviour, although VCT at Sero4 was asso-
ciated with an increased likelihood of stopping using
condoms with regular non-cohabiting partners by Sero5
(aRR 4.88, 95% CI 1.39-17.16). Coital frequency informa-
tion was not available at Sero4, but between Sero5 and
Sero6, there was no evidence for an impact of VCT on
changes in coital frequency with spouses or regular non-
cohabiting partners in the last week (Table 3). In
addition, there was no evidence to suggest any inter-
action between VCT use and gender in terms of any of
the sexual behaviour change outcomes.
In total 2,010 participants attended all three sero-
surveys, of whom 1,876 (93.3%) reported having ever
had sex. Among these, 82/1,876 (4.4%) used VCT twice
(at both Sero4 and Sero5) and 1,828/1,876 (97.4%) were
HIV-negative at Sero4. In crude analyses among HIV
negative individuals, those using VCT twice (at Sero4
and Sero5) were more likely to report increasing their
number of sexual partners (RR 2.10, 95% CI 1.06-4.14)
and acquiring a high-risk partner (RR 2.13, 95% CI 1.03-
4.38) between Sero4 and Sero6, compared to those who
did not use VCT twice. However there were no signifi-
cant impacts of VCT on any of the sexual behaviour
change outcomes in adjusted analyses.
Impact of VCT on HIV incidence
Between Sero4 and Sero5, HIV incidence among those
who did not use VCT at Sero4 was 0.86 per 100 person
years (95% CI 0.70-1.06), while it was 1.04 per 100 per-
son years (95% CI 0.56-1.94) among those who used
VCT. The corresponding incidence between Sero5 and
Sero6 was 0.66 per 100 person years (95% CI 0.46-0.93)
among those who did not use VCT at Sero5 and 0.48
per 100 person years (95% CI 0.20-1.16) among those
used VCT. In crude and adjusted analyses, VCT was not
significantly associated with changes in HIV-incidence
between either set of sero-survey rounds (Table 4).
Impact of VCT on sexual behaviour change among
HIV-positive individuals
Fewer indicators of sexual behaviour change could be
assessed among HIV-positive individuals due to small
sample sizes, and VCT use was not significantly associ-
ated with changes in any of these in crude or adjusted
analyses (Tables 5 and 6).
However, for some indicators, the measures of effect
seemed to go in opposite directions between Seros 4 and
5 and Seros 5 and 6. For example, a larger proportion of
HIV-positive individuals using VCT at Sero4 lost a
spouse by Sero5 (13.0% versus 11.4%, aRR 2.65, 95% CI
0.46-15.23) and acquired a regular non-cohabiting part-
ner by Sero5 (30.4% versus 17.5%, aRR 3.46, 95% CI
0.71-16.83) compared to those not using VCT. The op-
posite effect was seen between Seros 5 and 6. Compared
to those not using VCT, HIV-positive individuals using
VCT at Sero5 were more likely to acquire a spouse (10.3%
versus 2.7%, aRR 4.35, 95% CI 0.68-27.93) and to lose a
non-cohabiting partner (20.7% versus 11.7%, aRR 1.59,
95% CI 0.45-5.64) by Sero6. However, the confidence in-
tervals around all of these estimates are very wide.
In crude analyses, VCT use at both Sero4 and Sero5
seemed to be associated with an increased likelihood of
both stopping and starting using condoms at last sex
with spouse by the next round (Tables 5 and 6). However,
the numbers contributing to these analyses were very
small (six participants between Seros 4 and 5, eight partic-
ipants between Seros 5 and 6). As a result, the results were
not statistically significant, nor was it possible to adjust for
or investigate the effect of possible confounders.
Pooling the data for both sets of rounds (taking ac-
count of clustering for those who attended all three
rounds) did reveal some evidence for an association
Table 3 Change in sexual behaviour between Sero5 and Sero6 associated with VCT use at Sero5, HIV-negative
individuals (Continued)
Number times sex with regular non-cohabiting partner in last week#
75 % 29 %
No change 27 36.0 11 37.9 1 1
Increase 19 25.3 7 24.1 0.9 (0.30, 2.76) 0.83 (0.21, 3.32)
Decrease 29 38.7 11 37.9 0.93 (0.35, 2.50) 0.92 (0.27, 3.14)
¶All outcomes adjusted for age, sex, marital status, area of residence, level of education and previous VCT use as reported at the later sero-survey round.
*p ≤ 0.1, **p ≤ 0.05, ***p ≤ 0.001.
α‘Acquired or lost spouse’ was not adjusted for marital status (as this was the outcome).
ΩQuestions related to ‘casual’ rather than ‘high risk’ partners at Sero6, however, the two categories were considered comparable.
#Analyses conduced among those with relevant partner type at both rounds only.
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between VCT use and a reduction in some sexual risk
behaviours between rounds (results not shown). In these
analyses, HIV-positive individuals using VCT at the earl-
ier round seemed less likely to increase their number of
sexual partners in the last year by the next round as
compared to those not using VCT (aRR 0.22, 95% CI
0.05-1.01, p = 0.05).
Discussion
In this study, the overall uptake of VCT at the first two
sero-surveys during which it was offered was low (10%
and 17% at Seros 4 and 5 respectively [19]). A recent es-
timate of ART coverage among those in need in Kisesa
(based on individuals HIV-positive at Sero5) was also
low (just 2% - [20]). As in previous studies, our findings
Table 4 HIV incidence among initially HIV-negative participants, by VCT use at the earlier sero-survey round
N Person years Seroconversions Incidence per 100PY Crude rate ratio (95% CI) Adjusted rate ratio (95% CI)*
Attended Sero4 and Sero5
No VCT 3160 10133.8 87 0.86 (0.70-1.06) 1 1
VCT 299 959.1 10 1.04 (0.56-1.94) 1.21 (0.63-2.34) 1.13 (0.58-2.22)
Attended Sero5 and Sero6
No VCT 2343 4880.1 32 0.66 (0.46-0.93) 1 1
VCT 501 1031.0 5 0.48 (0.20-1.16) 0.74 (0.29-1.90) 0.69 (0.26-1.82)
*Adjusted for age, sex and previous VCT use as at reported at the later sero-survey round.
Table 5 Change in sexual behaviour between Sero4 and Sero5 associated with VCT use at Sero4, HIV-positive
individuals
N with outcome (%)
No VCT Had VCT Crude risk ratio (95% CI) Adjusted risk ratio (95% CI)¶
Number of sex partners in last year
115 % 23 %
No change 64 55.7 13 56.5 1 1
Increase 16 13.9 0 0.0 - -
Decrease 35 30.4 10 43.5 1.41 (0.56, 3.54) 0.88 (0.25, 3.02)
Acquired or lost a spouseα
114 % 23 %
No change 93 81.6 19 82.6 1 1
Acquired 8 7.0 1 4.3 0.61 (0.07, 5.18) 0.64 (0.06, 7.13)
Lost 13 11.4 3 13.0 1.13 (0.29, 4.35) 2.65 (0.46, 15.23)
Acquired or lost a regular non-cohabiting partner
114 % 23 %
No change 79 69.3 15 65.2 1 1
Acquired 20 17.5 7 30.4 1.84 (0.66, 5.12) 3.46 (0.71, 16.83)
Lost 15 13.2 1 4.3 0.35 (0.04, 2.86) 0.26 (0.02, 2.85)
Acquired or lost a high risk partner
115 % 22 %
No change 98 85.2 17 77.3 1 1
Acquired 10 8.7 1 4.5 0.58 (0.07, 4.80) 0.63 (0.05, 8.02)
Lost 7 6.1 4 18.2 3.29 (0.87, 12.48) 3.10 (0.50, 19.31)
Condom use at last sex with spouse#
68 % 12 %
No change 64 94.1 10 83.3 1 1
Stopped using 2 2.9 1 8.3 3.2 (0.26, 38.64) 0.99 (0.03, 34.27)
Started using 2 2.9 1 8.3 3.2 (0.26, 38.64) -
¶All outcomes adjusted for age, sex, marital status, area of residence, level of education and previous VCT use as reported at the later sero-survey round.
α‘Acquired or lost spouse’ was not adjusted for marital status (as this was the outcome).
#Analyses conducted among those with a spouse at both rounds only.
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with regard to the impact of VCT on sexual behaviour
change were mixed, with service use associated with
changes in some behaviours but not others. However, it
was encouraging that reductions in the numbers and
types of partnerships formed persisted across both sets
of sero-survey rounds.
We found no evidence for an impact of VCT on
changes in HIV incidence. While it is possible that a de-
clining incidence in the study area overall and a small
number of sero-conversions may have prevented us from
detecting this, a number of other studies have similarly
found no impact of VCT on changes in HIV incidence
[6,21].
It was perhaps unsurprising that HIV-negative individ-
uals were more likely to acquire a spouse after going for
VCT, as young couples in sub-Saharan African are fre-
quently advised to go for VCT before marriage. The in-
terpretation or significance of the acquisition or loss of a
spouse is somewhat different to the acquisition or loss of
a high-risk partner. While acquisition of the latter may
clearly be interpreted as a transition to higher risk behav-
iour, the acquisition of a spouse may be viewed as a shift to
Table 6 Change in sexual behaviour between Sero5 and Sero6 associated with VCT use at the Sero5, HIV-positive
individuals
N with outcome (%)
No VCT Had VCT Crude risk ratio (95% CI) Adjusted risk ratio (95% CI)¶
Number of sex partners in last year
110 % 29 %
No change 72 65.5 21 72.4 1 1
Increase 14 12.7 3 10.3 0.73 (0.19, 2.80) 0.41 (0.08, 2.12)
Decrease 24 21.8 5 17.2 0.71 (0.24, 2.10) 0.56 (0.13, 2.38)
Acquired or lost a spouseα
111 % 29 %
No change 88 79.3 23 79.3 1 1
Acquired 3 2.7 3 10.3 3.83 (0.72, 20.22) 4.35 (0.68, 27.93)
Lost 20 18.0 3 10.3 0.57 (0.16, 2.10) 0.68 (0.17, 2.63)
Acquired or lost a regular non-cohabiting partner
111 % 29 %
No change 90 81.1 22 75.9 1 1
Acquired 8 7.2 1 3.4 0.51 (0.06, 4.31) 0.21 (0.01, 3.25)
Lost 13 11.7 6 20.7 1.89 (0.65, 5.53) 1.59 (0.45, 5.63)
Acquired or lost a high risk or casual partnerΩ
110 % 29 %
No change 90 81.8 25 86.2 1 1
Acquired 11 10.0 3 10.3 0.98 (0.25, 3.79) 0.53 (0.10, 2.98)
Lost 9 8.2 1 3.4 0.4 (0.05, 3.31) 0.32 (0.02, 4.35)
Condom use at last sex with spouse#
61 % 18 %
No change 56 91.8 15 83.3 1 1
Stopped using 2 3.3 1 5.6 1.87 (0.16, 22.01) -
Started using 3 4.9 2 11.1 2.49 (0.38, 16.27) -
Number of times sex with spouse in last week#
62 % 19 %
No change 18 29.0 2 10.5 1 1
Increase 14 22.6 3 15.8 1.93 (0.28, 13.16) 3.37 (0.26, 44.11)
Decrease 30 48.4 14 73.7 4.2 (0.85, 20.65) 7.55 (0.84, 67.63)
¶All outcomes adjusted for age, sex, marital status, area of residence, level of education and previous VCT use as reported at the later sero-survey round.
α‘Acquired or lost spouse’ was not adjusted for marital status (as this was the outcome).
ΩQuestions related to ‘casual’ rather than ‘high risk’ partners at Sero6, however, the two categories were considered comparable.
#Analyses conducted among those with a spouse at both rounds only.
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lower-risk behaviour as people theoretically move from a
‘sexually active but single’ state to a more stable, settled re-
lationship. Conversely, the loss of a spouse (which might
not be volitional, for example if it occurred as a result
of widowhood) could be viewed as a transition to
higher-risk behaviour as people leave settled relation-
ships and return to a phase during which they may
seek out new sexual partners.
It was somewhat more surprising that HIV-negative
individuals using VCT at Sero4 were more likely to lose
a spouse by Sero5 than those not using VCT. However,
of the 201 HIV-negative individuals who lost a spouse
between Sero4 and Sero5, 75 of these cases (37.3%) were
as a result of widowhood. The observed association be-
tween VCT use and spousal loss between Seros 4–5 may
be linked to widowhood through reverse causality, as in-
dividuals with sick partners may have been more likely
to go and test than individuals with healthy partners.
Further qualitative research may help to elucidate the
reasons why people go (or don’t go) for VCT, the types
of information that clients receive and the perceived
importance of this information in helping people to
change their sexual behaviour.
Condom use among study participants was low overall
and VCT use was generally associated with little change
in this behaviour. The finding that VCT use at Sero4
was associated with an increased likelihood of stopping
using condoms at last sex with regular non-cohabiting
partners by Sero5 is difficult to interpret, but may relate
to the specific risk-profile of these non-cohabiting part-
ners and/or whether they had also been for VCT and
tested HIV-negative. A number of studies have found
VCT use to be associated with increases in condom use
[3,4,22] and so it was disappointing that we did not find
similar results in this study. Condom use has previ-
ously been reported to be low in this part of Tanzania
[23,24], and it is possible that negative attitudes to-
wards their use persist in spite of messages shared dur-
ing VCT. Low levels of condom use could also relate to
anecdotal evidence of problems relating to their avail-
ability or supply.
There were no statistically significant changes in sexual
behaviour associated with VCT use among HIV-positive in-
dividuals, except for a reduced likelihood of increasing the
number of sexual partners in the last year in the pooled
analysis. In the analyses done separately by round, for some
indicators the measures of effect seemed to go in opposite
directions between the two sets of rounds. For example, be-
tween Seros 4–5, individuals using VCT and testing
HIV-positive seemed more likely to lose a spouse but
to acquire a regular non-cohabiting partner by Sero5,
compared to those not using VCT. Conversely between
Seros 5–6, those testing HIV-positive seemed more
likely to acquire a spouse but to lose a regular partner
by Sero6. These results may have arisen simply as a
result of the small sample sizes which yielded non-
statistically significant results, but other factors could
also have been at play. For example, antiretroviral
therapy was more widely available in the study area
between Sero5 and Sero6, and this may have assisted
participants in regaining health and acquiring more
permanent spousal partners. Sero-sorting could also
have been taking place, with more people aware of their
HIV-status by the later sero-survey rounds, allowing them
to seek out other HIV-positive individuals with whom to
form more permanent partnerships.
The limitations of this study relate to the observational
nature of the data and to the pitfalls of working with
self-reported sexual behaviour data, which are subject to
recall and social desirability biases. We have previously
shown that in Kisesa, VCT tends to attract individuals
with higher risk sexual behaviours [19], and so as VCT
uptake increases, the associations between VCT use and
reductions in sexual risk behaviour among the general
population may be weaker. In addition, we may have
overstated the impacts of VCT if those who used the
service were more likely to report declines in their risk
behaviour compared to those who didn’t. However, the
community in Kisesa has been exposed to various HIV
information and education campaigns over a number
of years, and so all study participants are likely to
have had some degree of exposure to HIV prevention
messages.
Our ability to detect changes in levels of risk behav-
iour was limited by lack of knowledge of the sexual risk
profile and HIV-status of partners. Take for example
an individual who reported one sexual partner at both
rounds, but who had an HIV-negative partner at the
earlier round and an HIV-positive one at the later
round. In this scenario, there would have been an in-
crease in the level of risk between rounds which our
behaviour change index would have been incapable of
detecting. Further analyses among the subset of mar-
ried and co-habiting couples for whom partner HIV-
status are available may warrant investigation.
The strengths of this study relate to the fact that our
VCT use data were documented rather than self-reported,
and we were able to adjust for reported use of HIV counsel-
ling and testing services outside of sero-surveys, which
should have helped to reduce levels of measurement error
and residual confounding.
Conclusions
We found moderate but encouraging associations be-
tween VCT use and reductions in some sexual risk be-
haviours among HIV-negative participants, including
reductions in the number of sexual partners in the last
year, and a move to safer types of partnership. However, the
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overall uptake of VCT was low and we found no impacts of
VCT on changes in HIV incidence. There were also no sig-
nificant or consistent impacts of VCT on changes in sexual
behaviour among HIV-positive individuals, but small sam-
ple sizes may have prevented us from discovering these.
The impact of VCT services on sexual behaviour change
and HIV prevention will ultimately depend upon rates of
uptake, with further research required to better understand
processes of behaviour change following VCT use.
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